| Year | Title | Author(s) |
| 2023 |
Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface
Cancers |
Massudi, H Luo, JS Holien, JK Gadde, S Krishan, S Herath, M Koach, J Stevenson, BW Gorman, MA Venkat, P Mayoh, C Luo, XQ Parker, MW Cheung, BB Marshall, GM |
| 2021 |
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
Oncogene |
Cheung, BB Kleynhans, A Mittra, R Kim, PY Holien, JK Nagy, Z Ciampa, OC Seneviratne, JA Mayoh, C Raipuria, M Gadde, S Massudi, H Wong, IPL Tan, O Gong, A Suryano, A Diakiw, SM Liu, B Arndt, GM Liu, T Kumar, N Sangfelt, O Zhu, SZ Norris, MD Haber, M Carter, DR Parker, MW Marshall, GM |
| 2019 |
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Cancer Research |
Koach, J Holien, JK Massudi, H Carter, DR Ciampa, OC Herath, M Lim, T Seneviratne, JA Milazzo, G Murray, JE McCarroll, JA Liu, B Mayoh, C Keenan, B Stevenson, BW Gorman, MA Bell, JL Doughty, L Huttelmaier, S Oberthuer, A Fischer, M Gifford, AJ Liu, T Zhang, XL Zhu, SZ Gustafson, WC Haber, M Norris, MD Fletcher, JI Perini, G Parker, MW Cheung, BB Marshall, GM |